Australian scientists developed a novel antiviral that targets the SARS-CoV-2 PLpro enzyme, showing strong preclinical efficacy in reducing both acute and long COVID symptoms in mice.
Australian scientists developed a novel antiviral that targets the SARS-CoV-2 PLpro enzyme, showing strong preclinical efficacy in reducing both acute and long COVID symptoms in mice.